IMR Press / FBE / Volume 6 / Issue 1 / DOI: 10.2741/E686

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review

Clinical features and management of BRCA1 and BRCA2-associated prostate cancer

Show Less
1 Urology Service, Department of Surgery, Memorial SloanKettering Cancer Center, 1275 York Avenue, New York, NY, USA
2 Clinical Genetics Service, Department of Medicine, Memorial SloanKettering Cancer Center, 1275 York Avenue, New York, NY, USA
3 Department of Urology, Weill Cornell Medical College, 445 E 69th Street, New York, NY, USA
4 Departments of Medicine and Public Health, Weill Cornell Medical College, 445 E 69th Street, New York, NY, USA

*Author to whom correspondence should be addressed.

Academic Editor: Adriana De Siervi

Front. Biosci. (Elite Ed) 2014, 6(1), 15–30; https://doi.org/10.2741/E686
Published: 1 January 2014
(This article belongs to the Special Issue BRCA1 and BRCA2 role in cancer)
Abstract

It is thought that over forty percent of an individual's risk of developing prostate cancer (PCa) is related to familial and genetic factors. Although multiple genes have been implicated in the development of PCa, few confer as high a risk as mutations in the genes associated with early-onset breast cancer (BRCA1 and BRCA2). Not only do mutations in BRCA genes increase the risk of PCa, but they have also been related to adverse disease characteristics and outcomes. Therefore, a better understanding of the association between BRCA gene mutations and PCa may provide the backdrop for individualized management of patients with PCa who are carriers of a gene mutation. Such management may include an individualized approach to screening and treatment including chemotherapeutic regimens targeted to the underlying genetic mechanism of disease. In this paper, we review the evidence relating BRCA gene mutations to the risk of PCa, as well as outcomes and response to therapy, and suggest an approach to the management of such patients.

Keywords
BRCA1
BRCA2
Prostate Cancer
Risk
Management
Review
Share
Back to top